The key catalyst is the Phase 3 ROBBIN trial initiation in Q1 2027 and the interim pathologic response assessment of the first 100 patients expected in Q4 2027. The warrant milestones (60 patients by Q2 2027) will determine whether the additional ~$255M in potential proceeds materialize. Monitor site activation progress and any updates on regulatory submissions in Eurasian Economic Union countries.
Drugs in focus
AGEN drug pipeline →botensilimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
- Next catalyst
- None dated
What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $6.44entry
- T+1 · 11d ago +11.02%α +10.71% · $7.15
- T+5 · 5d ago +6.68%α +3.39% · $6.87
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Agenus reported Q3 2026 total revenue of $31.5M (up 4% YoY from $30.2M) and net income of $2.8M, its third consecutive quarter of positive operating income. The release highlighted first marketing authorizations for BOT+BAL in Armenia, strong Phase 2 neoadjuvant data in MSS colon cancer, and progress toward Phase 3 ROBBIN enrollment in Q1 2027. Cash increased to $86.9M following an $85M private placement in July, extending runway through Q3 2027.
Key Financial Metrics
Key Facts
- Total revenue $31.5M in Q3 2026 vs $30.2M in Q3 2025 (+4% YoY)
- Pre-commercial BOT+BAL product revenue $6.0M in Q3 2026 vs $6.4M in Q2 2026
- Non-cash royalty revenue $25.5M in Q3 2026 vs $28.1M in Q2 2026
- Operating income $11.4M in Q3 2026 vs operating loss of $4.6M in Q3 2025
- Net income $2.8M in Q3 2026 vs net income $63.9M in Q3 2025
- Cash, cash equivalents and short-term investments $86.9M at Sep 30, 2026 vs $18.7M at Jun 30, 2026
- July private placement provided ~$85M upfront gross proceeds with warrants for up to ~$255M additional
- First marketing authorizations for BOT+BAL granted in Armenia (conditional, one-year)
- ROBBIN Phase 3 on track for first patient enrollment in Q1 2027
- NEST and UNICORN Phase 2 studies reported ~30% pathologic complete response rates in MSS colon cancer with no recurrences at median follow-up of 19.2-32.2 months
Financial Impact
Total revenue $31.5M (Q3 2026) vs $30.2M (Q3 2025), +4% YoY; net income $2.8M vs $63.9M in prior year period (prior year included a large non-cash gain); cash position strengthened to $86.9M from $18.7M at June 30, 2026
Risk Factors
- Armenian marketing authorizations are conditional and valid for only one year, requiring annual renewal
- BOT+BAL remains investigational outside Armenia and is not FDA approved
- Non-cash royalty revenue ($25.5M of $31.5M total revenue) does not generate cash and is not recurring in nature
- Pre-commercial product revenue declined sequentially from $6.4M in Q2 to $6.0M in Q3
- Cash runway based on upfront proceeds only extends through Q3 2027; warrant exercise is contingent on milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-448637 |
| Document: agen-20261105.htm | 0001193125-26-448637 |
| Document: 0001193125-26-448637-index-headers.html | 0001193125-26-448637 |
| Document: 0001193125-26-448637-index.html | 0001193125-26-448637 |
| Document: 0001193125-26-448637.txt | 0001193125-26-448637 |
| 8-K Data (Synthetic) | 0001193125-26-448637 |
Track record
12 reports on AGEN
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.35 Now $6.29 −0.94% settles Feb 16
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers